Everest Medicines Ltd. (HK:1952)
HKEX:1952
Hong Kong Market
Holding HK:1952?
Track your performance easily

Everest Medicines Ltd. (1952) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

1952 Analyst Ratings

Hold
1Ratings
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Everest
Medicines Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1952 Stock 12 Month Forecast

Average Price Target

HK$25.00
▼(-25.37% Downside)
Based on 1 Wall Street analysts offering 12 month price targets for Everest Medicines Ltd. in the last 3 months. The average price target is HK$25.00 with a high forecast of HK$25.00 and a low forecast of HK$25.00. The average price target represents a -25.37% change from the last price of HK$33.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","30":"HK$30","14.25":"HK$14.25","19.5":"HK$19.5","24.75":"HK$24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,14.25,19.5,24.75,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,16.064615384615387,16.80923076923077,17.553846153846155,18.298461538461538,19.043076923076924,19.787692307692307,20.532307692307693,21.276923076923076,22.021538461538462,22.766153846153845,23.51076923076923,24.255384615384614,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,16.064615384615387,16.80923076923077,17.553846153846155,18.298461538461538,19.043076923076924,19.787692307692307,20.532307692307693,21.276923076923076,22.021538461538462,22.766153846153845,23.51076923076923,24.255384615384614,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,16.064615384615387,16.80923076923077,17.553846153846155,18.298461538461538,19.043076923076924,19.787692307692307,20.532307692307693,21.276923076923076,22.021538461538462,22.766153846153845,23.51076923076923,24.255384615384614,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.28,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.44,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.34,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.82,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.8,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.05,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29.75,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.3,"date":1698969600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.05,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.96,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$25.00Average Price TargetHK$25.00Lowest Price TargetHK$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
Hold
Reiterated
08/28/24
Everest Medicines Ltd (1952:HK) PT Lowered to HK$25 at CitiCiti analyst Wangbin Zhou lowered the price target on Everest Medicines Ltd (1952:HK) to HK$25.00 (from HK$27.00) while maintaining a Neutral rating.

1952 Analyst Recommendation Trends

Rating
Apr 23
Aug 23
Sep 23
Nov 23
Aug 24
Strong Buy
2
2
1
0
0
Buy
0
0
0
0
0
Hold
3
3
3
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
4
3
3
In the current month, 1952 has received 0 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 1952 average Analyst price target in the past 3 months is HK$25.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

1952 Financial Forecast

1952 Earnings Forecast

Next quarter’s earnings estimate for 1952 is -HK$1.16 with a range of -HK$1.16 to -HK$1.16. The previous quarter’s EPS was -HK$2.15. 1952 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.00% of the time in the same period. In the last calendar year 1952 has Outperformed its overall industry.
Next quarter’s earnings estimate for 1952 is -HK$1.16 with a range of -HK$1.16 to -HK$1.16. The previous quarter’s EPS was -HK$2.15. 1952 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.00% of the time in the same period. In the last calendar year 1952 has Outperformed its overall industry.

1952 Sales Forecast

Next quarter’s sales forecast for 1952 is HK$451.84M with a range of HK$451.84M to HK$451.84M. The previous quarter’s sales results were HK$326.73M. 1952 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 45.77% of the time in the same period. In the last calendar year 1952 has Outperformed its overall industry.
Next quarter’s sales forecast for 1952 is HK$451.84M with a range of HK$451.84M to HK$451.84M. The previous quarter’s sales results were HK$326.73M. 1952 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 45.77% of the time in the same period. In the last calendar year 1952 has Outperformed its overall industry.

1952 Stock Forecast FAQ

What is HK:1952’s average 12-month price target, according to analysts?
Based on analyst ratings, Everest Medicines Ltd.’s 12-month average price target is HK$25.00.
    What is HK:1952’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for HK:1952, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Everest Medicines Ltd. a Buy, Sell or Hold?
        Everest Medicines Ltd. has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Everest Medicines Ltd.’s share price target?
          The average share price target for Everest Medicines Ltd. is HK$25.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is HK$25.00 ,and the lowest forecast is HK$25.00. The average share price target represents -25.37% Decrease from the current price of HK$33.5.
            What do analysts say about Everest Medicines Ltd.?
            Everest Medicines Ltd.’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
              How can I buy shares of Everest Medicines Ltd.?
              To buy shares of HK:1952, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis